August 09, 2021
1 min read
Save
FDA grants orphan drug designation to ADX-2191 for retinitis pigmentosa
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The FDA has granted orphan drug designation to ADX-2191 for the treatment of retinitis pigmentosa, according to a press release from Aldeyra Therapeutics.
Currently, there are no approved drug treatments for retinitis pigmentosa.
“ADX-2191 has now received orphan designations for three distinct clinical indications, highlighting the broad platform potential of ADX-2191 to treat an array of rare retinal disorders,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, said in the release.
ADX-2191 (methotrexate for intravitreal injection) previously received the designation to treat primary vitreoretinal lymphoma and to prevent proliferative vitreoretinopathy.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.